WHO ICTRP trial
Clinical study for chimeric antigen receptor T cell immunotherapy in the…
ChiCTR2000031934 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2000031934 |
|---|---|
| Public title | Clinical study for chimeric antigen receptor T cell immunotherapy in the treatment of CD19 positive B cell lymphoma |
| Scientific title | Clinical trial for chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of CD19 positive B cell lymphoma |
| Primary sponsor | Anhui Provincial Cancer Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | B cell lymphoma |
| Interventions | Low dose:The infusion of 2.0x10^6 CAR+ T Cells/kg (+/-20%);Intermediate dose:The infusion of 6.0x10^6 CAR+ T Cells/kg (+/-20%);High dose:The infusion of 1.0x10^7 CAR+ T Cells/kg (+/-20%) |
| Registration date | Apr 15, 2020 |
| Target size | Low dose:3;Intermediate dose:3;High dose:3 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: